It's important to consider your comfort with risk before diving in.

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

New data presented at EACR 2026 highlighted anti-tumor activity, improved safety characteristics, and pharmacokinetic ...

Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own ...

Business combination transaction with Voyager Acquisition Corp. complete, creating a Nasdaq-listed, innovative biopharmaceutical company focused ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

This 'microbubble' startup just landed a $125 million round It closed its Bay Area HQ, but now it's part of a $900 million ...

Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.

Biotech firms develop drugs from living organisms; pharma from chemicals. Biotech products require a Biologics License Application for FDA approval. Investing focus should be on the long-term ...